Contineum MS drug stumbles in mid-stage trial
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
Winlevi is authorized in EU for the treatment of acne vulgaris
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
According to the ICMR-INDIAB study, 11.4% of adults in India have type 2 diabetes, while a staggering 15.3% are pre-diabetic
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
Subscribe To Our Newsletter & Stay Updated